Current Oncology | Kidney Cancer Awareness Month
Kidney cancer, also known as renal cell carcinoma, is a type of cancer that forms in the kidneys. It typically originates in the cells lining the small tubes within the organ. Treatment options include surgery, targeted therapy, and immunotherapy. March is the Kidney Cancer Awareness Month. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the field of kidney cancer, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field. The list of relevant papers is presented below.
“Prospective Evaluation of Kidney Function in Long-Term Survivors of Pediatric CNS Tumors”
by Natalia Stepien, Viktoria Handler, Johannes Gojo, Amedeo A. Azizi, Lisa Mayr, Chryssa Grylli, Daniela Schwarz, Monika Chocholous, Irene Slavc, Michael Boehm et al.
Curr. Oncol. 2022, 29(8), 5306–5315; https://doi.org/10.3390/curroncol29080421
Available online: https://www.mdpi.com/1718-7729/29/8/421
“Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma”
by Luisa M. Cardenas, Jasna E. Deluce, Shahrukh Khan, Omar Gulam, Saman Maleki Vareki, Ricardo Fernandes and Aly-Khan A. Lalani
Curr. Oncol. 2022, 29(8), 5426–5441; https://doi.org/10.3390/curroncol29080429
Available online: https://www.mdpi.com/1718-7729/29/8/429
“Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature”
by Alexius John, Lavinia Spain and Anis A. Hamid
Curr. Oncol. 2023, 30(1), 923–937; https://doi.org/10.3390/curroncol30010070
Available online: https://www.mdpi.com/1718-7729/30/1/70
“Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists”
by Irena Druce, Karine Tawagi, Julie L. V. Shaw, Andrea Ibrahim, Heather Lochnan and Michael Ong
Curr. Oncol. 2022, 29(7), 4665–4677; https://doi.org/10.3390/curroncol29070370
Available online: https://www.mdpi.com/1718-7729/29/7/370
“Virtual Resection: A New Tool for Preparing for Nephron-Sparing Surgery in Wilms Tumor Patients”
by Jasper M. van der Zee, Matthijs Fitski, Frank F. J. Simonis, Cornelis P. van de Ven, Aart J. Klijn, Marc H. W. A. Wijnen and Alida F. W. van der Steeg
Curr. Oncol. 2022, 29(2), 777–784; https://doi.org/10.3390/curroncol29020066
Available online: https://www.mdpi.com/1718-7729/29/2/66
“Trop-2 in Upper Tract Urothelial Carcinoma”
by Eisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, Ken Kuwahara, Takafumi Minami, Taigo Kato, Koji Hatano, Atsunari Kawashima, Motohide Uemura, Tetsuya Takao et al.
Curr. Oncol. 2022, 29(6), 3911–3921; https://doi.org/10.3390/curroncol29060312
Available online: https://www.mdpi.com/1718-7729/29/6/312
“Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art”
by Gianluigi Califano, Idir Ouzaid, Paul Laine-Caroff, Arthur Peyrottes, Claudia Collà Ruvolo, Benjamin Pradère, Vincent Elalouf, Vincent Misrai, Jean-François Hermieu, Shahrokh F. Shariat et al.
Curr. Oncol. 2022, 29(2), 687–697; https://doi.org/10.3390/curroncol29020060
Available online: https://www.mdpi.com/1718-7729/29/2/60
“Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies”
by Ioannis A. Voutsadakis
Curr. Oncol. 2022, 29(3), 1390–1407; https://doi.org/10.3390/curroncol29030117
Available online: https://www.mdpi.com/1718-7729/29/3/117
Relevant Special Issue:
“Current Advances in Clinical Genomics and Treatment of Urothelial Carcinoma”
Guest Editor: Dr. Panagiotis J. Vlachostergios
You are welcome to submit relevant papers to the journal Current Oncology. For any questions, feel free to contact us.
Current Oncology Editorial Office